Respiratory syncytial virus vaccine: where are we now and what comes next?

References

• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–1555.
   PubMed Web of Science ®Google Scholar
• Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004;113:1758–1764.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. New Engl J Med. 2009;360(6):588–598.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus–associated hospitalizations among children less than 24 months of age. Pediatrics. 2013 August;132(2).
   Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. New Engl J Med. 2005;352(17):1749–1759.
   PubMed Web of Science ®Google Scholar
• Pastula ST, Hackett J, Coalson J, et al. Hospitalizations for respiratory syncytial virus among adults in the United States, 1997–2012. Open Forum Infect Dis. 2017 Winter;4(1):ofw270. PMCID: PMC5414053.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179–868.
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized RSV monoclonal antibody, reduces hospitalization from RSV infection in high-risk infants. Pediatrics.1998;102:531–537.
   PubMed Web of Science ®Google Scholar
• Am K, Lr K, Fergie J, et al. The 2014-2015 national impact of the 2014 American academy of pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States. Am J Perinatol. 2018 Jan;35(2):192–200. Epub 2017 Sep 7.
   PubMed Web of Science ®Google Scholar
• Collins PL, Melero JA. Progress in understanding and controlling RSV: still crazy after all these years. Virus Res. 2011;162:80–89.
   PubMed Web of Science ®Google Scholar
• McClellan JS, Yongpink Y, Graham BS, et al. Structure of RSV fusion glycoprotein in the post fusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85:7788–7796.
   PubMed Web of Science ®Google Scholar
• Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus and metapneumoviruses. In: Knipe D, Howley P, Griffin D, editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1601–1646.
   Google Scholar
• Hall CB. Respiratory syncytial viral infections: pathology and pathogenicity. In: Weisman L, Groothuis J, editors. Contemporary diagnosis and management of respiratory syncytial virus infection. 5th ed. Newtown, PA: Handbooks in Health Care; 2000. p. 72–93.
   Google Scholar
• Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005;18:541–555.
   PubMed Web of Science ®Google Scholar
• Johnson JE, Gonzales RA, Olson SJ, et al. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20:108–119.
   PubMed Web of Science ®Google Scholar
• Hall CB, Douglas RG, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr. 1976;89:11–15.
   PubMed Web of Science ®Google Scholar
• Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 2000;1:398–401.
   PubMed Web of Science ®Google Scholar
• Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J. Virol. 2005;79:5353–5362.
   PubMed Web of Science ®Google Scholar
• Spann KM, Tran KC, Chi B, et al. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J. Virol. 2005;78:4363–4369.
   Web of Science ®Google Scholar
• Boyapalle S, Wong T, Garay J, et al. Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection. PLoS ONE. 2012;7:e29386.
   PubMed Web of Science ®Google Scholar
• Whelan JN, Tran KC, van Rossum DB, et al. Identification of respiratory syncytial virus nonstructural protein 2 residues essential for exploitation of the host ubiquitin system and inhibition of innate immune responses. J. Virol. 2016;90:6453–6463.
   PubMed Web of Science ®Google Scholar
• Kotelkin A, Belyakov IM, Yang L, et al. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response. J. Virol. 2006;80:5958–5967.
   PubMed Web of Science ®Google Scholar
• Chirkova T, Lin S, Oomens AG, et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J. Gen. Virol. 2015;96:2543–2556.
   PubMed Web of Science ®Google Scholar
• Triantafilou K, Kar S, Vakakis E, et al. Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax. 2013;68:66–75.
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98:708–715.
   PubMed Web of Science ®Google Scholar
• Hall CB. Prevention of infections with respiratory syncytial virus: the hopes and hurdles ahead. Rev Infect Dis. 1980;2(1):384–392.
   PubMedGoogle Scholar
• Groothuis JR, Eaf S, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524–1530.
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537.
   PubMed Web of Science ®Google Scholar
• Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007;195:1126–1136.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350:126–144.
   PubMed Web of Science ®Google Scholar
• Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163:693–698.
   PubMed Web of Science ®Google Scholar
• Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis. 2009;200:439–447.
   PubMed Web of Science ®Google Scholar
• Gonzalez PA, Prado CE, Leiva ED, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci USA. 2008;105:14999–15004.
   PubMed Web of Science ®Google Scholar
• Munir S, Hillyer P, Le Nouën C, et al. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog. 2011;7:e1001336.
   PubMed Web of Science ®Google Scholar
• Cespedes PF, Bueno SM, Ramirez BA, et al. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. Proc Natl Acad Sci USA. 2014;111:E3214–E3223.
   PubMed Web of Science ®Google Scholar
• Durbin JE, Durbin RK. Respiratory syncytial virus–induced immunoprotection and immunopathology. Viral Immunol. 2004;17:370–380.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Openshaw PJM, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med. 1988;163:1163–1168.
   Google Scholar
• Johnson TR, Varga SM, Braciale TJ, et al. VBeta14+ T cells mediate the vaccine-enhanced disease induced by immunization with Respiratory Syncytial Virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol. 2004;78:8753–8760.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–434.
   PubMed Web of Science ®Google Scholar
• Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 1969;89:449–463.
   PubMed Web of Science ®Google Scholar
• Varga SM, Wang X, Welsh RM, et al. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity. 2001;15:637–646.
   PubMed Web of Science ®Google Scholar
• Connors M, Giese NA, Kulkarni AB, et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 1994;68:5321–5325.
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Dyer KD, Domachowske JB. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res. 2009;83:1–9.
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 1997;186:421–432.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Correia BE, Chen M, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol. Biol. 2011;409:853–866.
   PubMed Web of Science ®Google Scholar
• McLellan JS. F Protein Structures and Their Implications for Humoral Immunity. Presented at the 8th Respiratory Syncytial Virus Symposium; 2012; Santa Fe, NM.
   Google Scholar
• Graham BS. Future of RSV vaccine development. Presented at the 8th Respiratory Syncytial Virus Symposium; 2012; Santa Fe, NM, USA.
   Google Scholar
• Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J. 2008;27:207–212.
   PubMed Web of Science ®Google Scholar
• Magro M., et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci USA. 2012;109:3089–3094.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342:592–598.
   PubMed Web of Science ®Google Scholar
• Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015;7:309ra162.
   PubMed Web of Science ®Google Scholar
• Gilman MS, Sm M, Mas V, et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog. 2015 Jul 10;11(7):e1005035. eCollection 2015 Jul.
   PubMed Web of Science ®Google Scholar
• Corti D, Bianchi S, Vanzetta F, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013 Sep 19;501(7467):439–443. Epub 2013 Aug 18.
   PubMed Web of Science ®Google Scholar
• Langley JM, Aggarwal N, Toma A, et al. A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis. 2017 Jan 1;215(1):24–33.
   PubMed Web of Science ®Google Scholar
• RosseyI, Morgan SA, Gilman MS, et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun. 2017;8:14158.
   PubMed Web of Science ®Google Scholar
• Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013;372:259–284.
   PubMed Web of Science ®Google Scholar
• Bermingham A, Collins PL. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A. 1999;96:11259–11264.
   PubMed Web of Science ®Google Scholar
• Buchholz UJ, Cunningham CK, Muresan P, et al. Respiratory Syncytial Virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1114 study team. J Infect Dis. 2018;217(9):1338–1346.
   PubMed Web of Science ®Google Scholar
• McFarland EJ, Karron R, Muresan P, et al. Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children. J Infect Dis. 2018;217:1347–1355.
   PubMed Web of Science ®Google Scholar
• Karron RA, Luongo C, Thumar B, et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med. 2015;7:312ra175.
   PubMed Web of Science ®Google Scholar
• Lindell DM, Morris SB, White MP, et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE. 2011;6:e21823.
   PubMed Web of Science ®Google Scholar
• Langley JM, Aggarwal N, Toma A, et al. A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis. 2017;215:24–33.
   PubMed Web of Science ®Google Scholar
• Schepens B, Schotsaert M, Saelens X. Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen. Immunotherapy. 2015;7:203–206.
   PubMed Web of Science ®Google Scholar
• Creech CB, Dekker CL, Ho D, et al. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother. 2013;9:2548–2557.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 2013;207:248–256.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Higgins D, Nunes MC, et al. Respiratory syncytial virus network (ReSViNET) foundation. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018 Jun 18;S1473–S3099(18):30292–30295.
   Google Scholar
• Steff AM, Monroe J, Friedrich K, et al. Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle preexposed to bovine RSV. Nat Commun. 2017;8:1085.
   PubMed Web of Science ®Google Scholar
• Yamin D, Jones FK, DeVincenzo JP, et al. Vaccination strategies against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13239–13244.
   PubMed Web of Science ®Google Scholar
• Poletti P, Merler S, Ajelli M, et al. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings. BMC Med. 2015;13:49.
   PubMed Web of Science ®Google Scholar
• Giersing BK, Modjarrad K, Kaslow DC, et al. WHO product development for vaccines advisory committee. Report from the world health organization’s product development for vaccines advisory committee (PDVAC) meeting, Geneva, 7–9th Sep 2015. Vaccine. 2016 Jun 3;34(26):2865–2869.
   PubMed Web of Science ®Google Scholar